Compound targeting il-23a and tnf-alpha and uses thereof

A compound comprising a first polypeptide and a second polypeptide, wherein:

• (A) said first polypeptide comprises:
• (i) a light chain variable domain of a first immunoglobulin (VL1) specific for a first target protein;
• (ii) a heavy chain variable domain of a second immunoglobulin (VH2) specific for a second target protein;
• and
• (iii) a hinge region, a heavy chain constant region 2 (CH2) and a heavy chain constant region 3 (CH3);
• and
• (B) said second polypeptide comprises:
• (i) a light chain variable domain of the second immunoglobulin (VL2) specific for said second target protein;
• (ii) a heavy chain variable domain of the first immunoglobulin (VH1) specific for said first target protein;
• wherein:
• (i) said VL1 and VH1 associate to form a binding site that binds said first target protein;
• (ii) said VL2 and VH2 associate to form a binding site that binds said second target protein;
• (iii) said heavy chain constant region 2 (CH2) comprises a tyrosine at position 252, a threonine at position 254 and a glutamic acid a position 256, numbered according to the EU index as in Kabat;
• and
• (iv) said first target protein is TNF-alpha and said second target protein is IL-23A or said first target protein is IL-23A and said second target protein is TNF-alpha,
• wherein:
• (i) said VL1 comprises SEQ ID NO:2, said VH1 comprises SEQ ID NO:
• 1, said VL2 comprises SEQ ID NO:8 and said VH2 comprises SEQ ID NO:7;
• or
• (ii) said VL1 comprises SEQ ID NO:4 or 6, said VH1 comprises SEQ ID NO:3 or 5, said VL2 comprises SEQ ID NO:8 and said VH2 comprises SEQ ID NO:7;
• or
• (iii) said VL1 comprises SEQ ID NO:8, said VH1 comprises SEQ ID NO:7, said VL2 comprises SEQ ID NO:2 and said VH2 comprises SEQ ID NO:
• 1;
• or
• (iv) said VL1 comprises SEQ ID NO:8, said VH1 comprises SEQ ID NO:7, said VL2 comprises SEQ ID NO:4 or 6 and said VH2 comprises SEQ ID NO:3 or 5.